Agaricus Bisporus and Influenza Vaccination Response
Key facts
- Who runs it
- Maastricht University Medical Center
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 88 people enrolled
- Started
- 14 Sept 2023
- Ended
- 30 May 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Influenza vaccine
- Agaricus bisporus capsules
- Control capsules
- Record updated
- 24 March 2025
Who can take part
- Age
- 59 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Aged 60 years or older during influenza season 2023/2024 (in line with RIVM guidelines)
- BMI between 20 and 35 kg/m2
- Willing to abstain from mushrooms other than the capsules containing a mushroom powder as provided by us during the study period
- Willing to keep the intake of fish oil, Zinc, Selenium and (vitamin) supplements constant
- Willing to abstain from products / supplements enriched with Vitamin D
- Willing to abstain from products / supplements enriched with plant sterols or stanols
- Willing to abstain from products / supplements enriched with (β)glucans or fungi
- Willing to abstain from products / supplements that are mentioned to "boost your immune system"
- Willing to abstain from (products enriched in) pre/pro-biotics
- Willing to abstain from products/supplements enriched with ergothioneine
Who cannot take part
- Already received influenza vaccination in 2023
- Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
- Regular use of soft and/or hard drugs
- Allergy to mushrooms
- Known allergic reaction to an active component or other components of the vaccine (e.g. Chicken Eggs)
- Using medication for diseases known to affect inflammation/immunity (e.g. inhaled corticosteroids and prednisone)
- Excessive alcohol use (>20 consumptions per week)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There are numerous in vitro and animal studies that suggested that mushrooms beneficially influence the immune system. We have recently shown that a wild isolate of the edible Agaricus bisporus mushroom had a clear effect on parameters reflecting a better function of the immune system, both in vitro and in vivo in animals. The question now is whether this efficacy can also be translated to humans. In humans, measuring the antibody response is the golden standard to evaluate immune function. If Agaricus bisporus powder indeed has beneficial effects on the immune system, people with overweight or obesity and higher age might benefit from consuming Agaricus bisporus powder prior to receiving the influenza vaccination.
The 2 groups in the trial
- Agaricus bisporus groupTreatment being tested
Dietary supplement: 10 capsules containing 500 mg Agaricus bisporus powder each
Treatment: Influenza vaccine and Agaricus bisporus capsules
- Placebo groupPlacebo, for comparison
Dietary supplement: 10 placebo capsules, capsules that do not contain Agaricus bisporus powder
Treatment: Influenza vaccine and Control capsules
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mushboost: Evaluating the Effect of Agaricus Bisporus Powder Intake on the Vaccination Response to an Influenza Vaccine
- Record updated
- 24 March 2025